FDA Panel Backs Moderna Flu Shot; CFO Exits Weigh on PFE

Moderna ($MRNA) received a unanimous vote from the FDA's Vaccines and Related Biological Products Advisory Committee in favor of the benefit-risk profile of mRNA-1010, its investigational seasonal influenza vaccine. The FDA's Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026. Jefferies noted that FDA decisions aligned with advisory committee recommendations 84% of the time between 2020 and 2025, suggesting a favorable path forward. Separately, the FDA announced it is requesting updates to prescribing information for testosterone therapies, a move that impacts AbbVie ($ABBV), which closed down 2.14% at $216.49.

Pfizer ($PFE) announced the departure of its Chief Financial Officer and named an interim head of finance while affirming its full-year 2026 outlook. The CFO transition tested investor confidence, with recent drug approvals providing a foundation for shareholders seeking evidence that cost cuts and newer medicines can support the earnings outlook. Eli Lilly ($LLY) continues its manufacturing expansion, with CEO Dave Ricks leading a $50 billion investment described as a manufacturing Marshall Plan to safeguard the company's lead in obesity and diabetes treatments. Separately, Regeneron Pharmaceuticals ($REGN) has been drawing attention for its Sanofi collaboration profit stream, which is reshaping the company's financial core beyond pipeline-focused analysis.

Radioligand therapies (RLTs) generated significant discussion at ASCO 2026, though experts noted that certain limitations must be addressed to facilitate widespread use in cancer care. Commercial and tolerability concerns remain as the field evaluates the practical implementation of these treatments. CytomX Therapeutics ($CTMX) expanded its research collaboration with Regeneron ($REGN) on June 3 to develop next-generation conditionally-activated bispecific cancer therapies, combining CytomX's PROBODY masking platform with Regeneron's Veloci-Bi technology. Analysts have highlighted $LLY and other companies as potential beneficiaries of the next wave of medical AI applications in drug development.

Major healthcare stocks declined in Thursday's trading session. Johnson & Johnson ($JNJ) fell 2.48% to close at $228.39, while Merck ($MRK) dropped 1.36% to $113.87. Despite near-term pressure, $JNJ was featured in research highlighting Dividend Kings with more than 50 years of consecutive dividend increases. Citi reiterated its Buy rating on Abbott Laboratories ($ABT) on June 17, stating that the company's individual business segments may be worth more than the market currently values the company as a whole.

The global automated liquid handling systems market was valued at approximately $2.7 billion in 2025 and is expected to reach $2.9 billion in 2026, growing to $6.9 billion by 2035 at a compound annual growth rate of 9.8%, according to Healthcare Foresights. The ECG patch and Holter monitor market showed similar growth dynamics, valued at approximately $1.87 billion in 2025 and expected to reach $2.04 billion in 2026, expanding to $3.92 billion by 2035 at a 9.2% CAGR. Abbott Laboratories ($ABT) and Thermo Fisher Scientific ($TMO) are among key players in these expanding diagnostic and laboratory automation markets.